finance
MiNK Therapeutics Reports agenT-797 Produces Context-Dependent Immune Responses in Cancer and ARDS
MiNK Therapeutics presented clinical data at the ASGCT 2026 meeting showing its off-the-shelf iNKT cell therapy agenT-797 drove different immune responses in patients with solid tumors and those with acute respiratory distress syndrome. The same product batch from one donor activated pro-inflammatory pathways in cancer patients and anti-inflammatory effects in ARDS patients without genetic…
May 12, 7:35 AM·1m read1 source
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
MiNK Therapeutics announced clinical findings at the American Society of Gene and Cell Therapy Annual Meeting in Boston showing that its allogeneic invariant natural killer T cell therapy produces disease-appropriate immune responses depending on the patient's condition.
The therapy, agenT-797, drove a TH1 pro-inflammatory immune program in patients with solid tumors and a TH2 anti-inflammatory response in patients with acute respiratory distress syndrome. The same product, manufactured from a single donor batch without genetic modification, was used across both groups.
Data from 34 patients with solid tumors included tumor responses with one case of complete metastatic remission. In 20 patients with ARDS, the treatment was associated with improved survival and pathogen clearance.
The findings were consistent across multiple manufacturing batches and donors. This supports the reproducibility of the manufacturing process at scale for a broadly deployable cell therapy. The results underscore the intrinsic biology of iNKT cells, which allows the same therapy to generate context-dependent effects without disease-specific engineering.
The company stated this approach enables expansion into multiple disease indications from one product.
The data support advancement into a randomized Phase 2 trial in acute lung injury, identified as study C-1300-02. Preliminary data from that trial are expected in 2026. The poster presenting the findings, numbered 3371, is scheduled for May 14, 2026.
